SAN DIEGO -- (BUSINESS WIRE) -- SynteractHCR, a leading full-service global contract research organization (CRO), is pleased to announce Dr. Stephan de la Motte, chief medical advisor, as one of the 2014 PharmaVOICE 100, an annual list of the most inspiring people in the life sciences industry. PharmaVOICE magazine releases the top 100 list and identifies industry thought leaders and innovators that have the biggest impact on the entire field. De la Motte is the fourth executive from SynteractHCR named to the list in the past six years.
With nearly 30 years of experience, Dr. de la Motte is renowned for his scientific and medical expertise and clinical trial knowledge of phase I, II and III studies. Over the course of his career, he has served as coordinating investigator for six clinical trials, as principal investigator for 60 trials and as investigator for 80 trials. His impressive contributions include delivering 33 scientific presentations at medical congresses and being featured in 22 peer-reviewed journals. Dr. de la Motte’s therapeutic experience includes general medicine, clinical pharmacology, pharmacology and toxicology, anesthesia, internal medicine, psychiatry, neurosurgery, neurophysiology and military medicine. He recently completed a white paper titled “Orphan Indications and Clinical Trials: Why Rare Diseases Warrant Special Treatment,” explaining the unique characteristics of clinical trials in rare diseases and orphan treatments.
“Stephan has made his mark in the clinical research field,” said Wendel Barr, CEO of SynteractHCR. “His selection as one of the PharmaVOICE 100 reflects the fact that he ‘connects the dots’ in a way that is seldom seen in our industry. He successfully and deftly communicates our values to both our clients and our employees, which has helped propel us to become a leader in the drug development space.”
The 2014 honorees were announced in the August 2014 issue of PharmaVOICE magazine. Each year, PharmaVOICE receives thousands of nominations from readers who collectively nominate and vote for their choice of the most influential leaders in the life-sciences industry. According to the publication, honorees “positively impact their peers, their colleagues, their companies, their communities, as well as the industry at large through their actions.” The nominees must exhibit strong leadership qualities, fearless and unique approaches to problems, and innovation in strategies, products and services. Submissions are provided to PharmaVOICE by colleagues who believe their nominee fits the required criteria.
About SynteractHCR (www.synteracthcr.com)
SynteractHCR is a full-service contract research organization with a successful two-decade track record supporting biotechnology, medical device and pharmaceutical companies in all phases of clinical development. SynteractHCR has conducted Phase I-IV studies on six continents and in more than 50 countries, offering expertise across multiple therapeutic areas and with notable depth in oncology, CNS, infectious disease, endocrinology, cardiovascular and respiratory, among other indications. With its “Shared Work – Shared Vision” philosophy and ICD+ approach, SynteractHCR provides customized services collaboratively and cost effectively, ensuring on-time delivery of quality data so clients get to decision points faster.